[go: up one dir, main page]

CN1778334B - Chinese Medicine Dropping Pills for Treating Angina Pectoris of Coronary Heart Disease - Google Patents

Chinese Medicine Dropping Pills for Treating Angina Pectoris of Coronary Heart Disease Download PDF

Info

Publication number
CN1778334B
CN1778334B CN 200410072927 CN200410072927A CN1778334B CN 1778334 B CN1778334 B CN 1778334B CN 200410072927 CN200410072927 CN 200410072927 CN 200410072927 A CN200410072927 A CN 200410072927A CN 1778334 B CN1778334 B CN 1778334B
Authority
CN
China
Prior art keywords
membrane
ultrafiltration
chinese medicine
extract
dripping pill
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN 200410072927
Other languages
Chinese (zh)
Other versions
CN1778334A (en
Inventor
郑永锋
李旭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tasly Pharmaceutical Group Co Ltd
Original Assignee
Tianjin Tasly Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Tasly Pharmaceutical Co Ltd filed Critical Tianjin Tasly Pharmaceutical Co Ltd
Priority to CN 200410072927 priority Critical patent/CN1778334B/en
Publication of CN1778334A publication Critical patent/CN1778334A/en
Application granted granted Critical
Publication of CN1778334B publication Critical patent/CN1778334B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A Chinese medicine in the form of dripping pill for treating coronary heart disease and angina pectoris is prepared from red sage root, Chuang-xiong rhizome and borneol through extracting the liquid extract from red sage root and Chuan-xiong rhizome in water or alcohol, clarifying, ultrafiltering, concentrating, adding borneol and preparing dripping pills.

Description

治疗冠心病心绞痛的中药滴丸 Chinese Medicine Dropping Pills for Treating Angina Pectoris of Coronary Heart Disease

技术领域technical field

本发明涉及一种应用超滤工艺制备的中药。具体而言,本发明涉及一种应用超滤工艺制备的中药滴丸。The invention relates to a traditional Chinese medicine prepared by an ultrafiltration process. Specifically, the invention relates to a traditional Chinese medicine dripping pill prepared by an ultrafiltration process.

背景技术Background technique

膜分离技术(Membrane Separation Technique)是一项新兴的高效分离技术,已被国际公认为20世纪末至21世纪中期最有发展前途的一项重大高新生产技术。超滤(Ultrafiltration,UF)技术是一种膜分离技术,其基本原理是利用膜孔选择性筛分性能,以分离、提纯和浓缩物质。超滤方法,是利用高分子材料制成的各向异性膜(即不对称膜)为过滤介质,在常温条件下,依靠一定的压力和流速,使溶液流经膜面,迫使低分子量物质透过膜,而使高分子物质被截留。Membrane separation technology (Membrane Separation Technique) is a new high-efficiency separation technology, which has been internationally recognized as the most promising high-tech production technology from the end of the 20th century to the middle of the 21st century. Ultrafiltration (UF) technology is a membrane separation technology whose basic principle is to use the selective screening performance of membrane pores to separate, purify and concentrate substances. The ultrafiltration method uses an anisotropic membrane (that is, an asymmetric membrane) made of polymer materials as the filter medium. Under normal temperature conditions, relying on a certain pressure and flow rate, the solution flows through the membrane surface, forcing low molecular weight substances to permeate. Through the membrane, the polymer substances are intercepted.

由于超滤方法为物理方法,具有不须反复加热,没有“相态”变化,破坏有效成分的可能性较其它通用方法为少,工艺流程短等特点,因而其应用于提取中药有效成分的研究日益活跃,部分产品已从实验室研究走向工业生产.解放军304医院王世岭等人用超滤法提取黄芩中有效成分黄芩甙,结果表明超滤法在产率、纯度方面均较常法为优,且一次超滤即可达到注射剂要求,不需再行精制,工艺简单,生产周期可缩短1~2倍(王世岭,郑殿宝“超滤法提取黄芩甙的初步考察”,中成药研究,1988(3):5).王世岭等还进一步研究了超滤法提取黄芩甙的最佳工艺条件,实验结果证明选用适宜孔径(截留分子量为6000~10000)的超滤膜是提高黄芩甙收率和质量的关键,同时升高药液温度或降低浓度,严格控制pH值(酸化时pH=1.5,碱溶时pH=7.0),可显著提高超滤速度,获得最佳产出效果(王世岭,“超滤法一次提取黄芩甙的工艺研究”,中成药,1994,16(3):2).许金林等将超滤法(聚砜膜,截留分子量6000)用于植酸的制备中,植酸得率为86.4%,比常规的植酸盐法提高12.6%,且超滤法所得植酸几乎不含无机磷,外观透明几近无色(许金林,许杰,汪远金“膜分离技术制备植酸的研究”,中国医药工业杂志,1994,25(4):150).何昌生等应用超滤技术分离精制甜菊糖甙,采用超薄型板式超滤器和截留分子量为10000的醋酸纤维素膜(CA膜)对甜菊糖甙进行净化现场实验,其工艺流程合理可行.超滤器性能稳定,膜的脱色性能和除杂质效果良好,可较好地解决甜菊糖甙生产中常常出现的沉淀和灌封时起泡问题(何昌生,王炳南,朱姗姗“甜菊糖甙超滤的应用研究”,水处理技术,1994,20(2):89).黄自强采用超滤膜(截留分子量为4000和10000的聚砜膜)精制油茶皂甙,与国内大都采用的漂白法、再结晶法、醇醚沉淀法及碱式盐沉淀法比较,超滤法流程简单,效率高,费用低,对除去粗油茶皂甙中的油脂、色素、糖类及其他亲水性强的杂质,都能达到预期效果(黄自强,“超滤膜法精制油茶皂甙初探”水处理技术,1995,21(2):99).南京中医药大学郭立玮等比较研究了水醇法与超滤法澄清山茱萸制剂对其制剂所含成分的影响,结果证实超滤法对去除药液中糖类杂质更为有效,截留分子量为10000的超滤膜对马钱素(分子量为384)无明显影响,但截留分子量为1000的膜使马钱素损失50%左右(郭立玮,彭国平,潘扬等“水醇法与膜分离法精制含山茱萸中药制剂的比较研究”,中成药,1999,21(2):59).王成章等采用超滤法(聚砜膜,截留分子量30000)和聚酰胺树脂吸附洗脱法对银杏叶的乙醇提取液进行分离、纯化,经高效液相色谱(HPLC)检测,银杏黄酮甙含量在45%左右,得率为0.5%~0.7%,较常规水蒸气蒸馏法、有机溶剂提取法为优,而且在超滤工艺中可减少废水排放,保护环境,降低生产成本,提高经济效益(王成章,郁青,谭卫红等“超滤在纯化银杏叶黄酮甙中的应用”,林业科技通讯,1997,(2):21).Because the ultrafiltration method is a physical method, it has the characteristics of no need for repeated heating, no "phase state" change, less possibility of destroying active ingredients than other general methods, and short process flow, so it is applied to the research of extracting active ingredients of traditional Chinese medicine It is becoming more and more active, and some products have moved from laboratory research to industrial production. Wang Shiling and others in the PLA 304 Hospital used ultrafiltration to extract the active ingredient baicalin in Scutellaria baicalensis. The results showed that the ultrafiltration method was better than the conventional method in terms of yield and purity. And once ultrafiltration can meet the requirement of injection, no further refinement is needed, the process is simple, and the production cycle can be shortened by 1 to 2 times (Wang Shiling, Zheng Dianbao "Preliminary investigation of extracting baicalin by ultrafiltration", Chinese patent medicine research, 1988 (3 ): 5). Wang Shiling and others have further studied the optimal process conditions for extracting baicalin by ultrafiltration. The experimental results prove that the ultrafiltration membrane with suitable pore size (molecular weight cut-off is 6000~10000) is the best way to improve the yield and quality of baicalin. The key is to increase the temperature of the liquid medicine or reduce the concentration at the same time, and strictly control the pH value (pH=1.5 during acidification, pH=7.0 during alkali dissolution), which can significantly increase the ultrafiltration speed and obtain the best output effect (Wang Shiling, "Ultrafiltration A study on the process of extracting baicalin at one time", Chinese patent medicine, 1994, 16 (3): 2). Xu Jinlin et al. used ultrafiltration (polysulfone membrane, molecular weight cut-off 6000) in the preparation of phytic acid, and the yield of phytic acid It is 86.4%, 12.6% higher than the conventional phytate method, and the phytic acid obtained by the ultrafiltration method almost does not contain inorganic phosphorus, and the appearance is transparent and almost colorless (Xu Jinlin, Xu Jie, Wang Yuanjin "Research on the Preparation of Phytic Acid by Membrane Separation Technology" , Chinese Journal of Pharmaceutical Industry, 1994, 25 (4): 150). He Changsheng and other applications of ultrafiltration technology to separate and refine stevioside, using ultra-thin plate ultrafilter and cellulose acetate membrane (CA membrane) with a molecular weight cut-off of 10000 ) field experiments on stevioside purification, the process flow is reasonable and feasible. The performance of the ultrafilter is stable, the decolorization performance of the membrane and the effect of removing impurities are good, and it can better solve the precipitation and potting that often occur in the production of stevioside. Foaming problem (He Changsheng, Wang Bingnan, Zhu Shanshan "Research on the application of stevioside ultrafiltration", Water Treatment Technology, 1994, 20(2): 89). Huang Ziqiang used ultrafiltration membranes (molecular weight cut-offs of 4000 and 10000 Compared with the bleaching method, recrystallization method, alcohol ether precipitation method and basic salt precipitation method that are mostly used in China, the ultrafiltration process is simple, efficient, and low in cost. Oils, pigments, sugars and other highly hydrophilic impurities in the water can achieve the desired effect (Huang Ziqiang, "Preliminary Study on the Purification of Camellia Camellia Saponin by Ultrafiltration Membrane Method", Water Treatment Technology, 1995, 21(2): 99). Guo Liwei from Nanjing University of Traditional Chinese Medicine compared and studied the effects of water-alcohol method and ultrafiltration method on the clarification of Cornus officinalis preparations on the ingredients contained in the preparations. The ultrafiltration membrane has no obvious effect on loganin (molecular weight is 384), but the membrane with a molecular weight cut-off of 1000 makes loganin lose about 50% Right (Guo Liwei, Peng Guoping, Pan Yang, etc. "Comparative research on refining traditional Chinese medicine preparations containing Cornus officinalis by water-alcohol method and membrane separation method", Chinese Patent Medicine, 1999, 21 (2): 59). Wang Chengzhang et al. Sulfone membrane, molecular weight cut-off 30000) and polyamide resin adsorption and elution method are used to separate and purify the ethanol extract of Ginkgo biloba leaves. After detection by high performance liquid chromatography (HPLC), the content of glycosides in Ginkgo biloba is about 45%, and the yield is 0.5% %~0.7%, compared with conventional steam distillation and organic solvent extraction, it is superior, and can reduce wastewater discharge in the ultrafiltration process, protect the environment, reduce production costs, and improve economic benefits (Wang Chengzhang, Yu Qing, Tan Weihong, etc. Application of ultrafiltration in the purification of flavonoid glycosides from Ginkgo biloba leaves", Forestry Science and Technology Communication, 1997, (2): 21).

超滤技术应用于中药制剂的生产虽有其独特的优点,但其推广应用的程度仍然十分有限,究其原因,尚存在以下问题:Although the application of ultrafiltration technology in the production of traditional Chinese medicine preparations has its unique advantages, the extent of its application is still very limited. The reason is that there are still the following problems:

(1)中草药成分复杂,特别是许多复方制剂,有效成分还未完全清楚,因此在将超滤技术应用于中草药制剂之前需要进行十分深入的研究。例如由于成分的复杂性,在未进行大量的药理和临床研究试验充分评价超滤对中药制剂中各成分的药效影响程度之前,不可能将超滤法应用于大多数中药制剂的生产。(1) The composition of Chinese herbal medicine is complex, especially in many compound preparations, the active ingredients have not been fully understood, so it needs to be thoroughly studied before applying ultrafiltration technology to Chinese herbal medicine preparations. For example, due to the complexity of the components, it is impossible to apply ultrafiltration to the production of most traditional Chinese medicine preparations before a large number of pharmacological and clinical research tests are conducted to fully evaluate the effect of ultrafiltration on the efficacy of each component in traditional Chinese medicine preparations.

(2)膜材料的品种少,膜孔径分布宽,性能欠稳定。在中药制剂生产中使用过的超滤膜材料有醋酸纤维素、聚丙烯腈、聚砜、磺化聚砜、聚砜酰胺等。按其对水的亲和性分类,大致可分为两类:疏水性膜材料和亲水性膜材料。醋酸纤维素、磺化聚砜等亲水性膜材料对溶质吸附少,截留分子量较小,但热稳定性差,机械强度、抗化学药品性、抗细菌侵蚀能力通常不高;聚砜等疏水性膜材,机械强度高,耐高温、耐溶剂、耐生物降解,但因分子链中含有大量疏水性基因或链节,并带有较多静电荷,因而膜透水速度低,抗污染能力较低。(2) There are few types of membrane materials, the membrane pore size distribution is wide, and the performance is not stable. The ultrafiltration membrane materials used in the production of traditional Chinese medicine preparations include cellulose acetate, polyacrylonitrile, polysulfone, sulfonated polysulfone, polysulfone amide, etc. According to its affinity to water, it can be roughly divided into two categories: hydrophobic membrane materials and hydrophilic membrane materials. Hydrophilic membrane materials such as cellulose acetate and sulfonated polysulfone have less adsorption of solutes and a smaller molecular weight cut-off, but poor thermal stability, mechanical strength, chemical resistance, and bacterial erosion resistance are usually not high; polysulfone and other hydrophobic Membrane material has high mechanical strength, high temperature resistance, solvent resistance, and biodegradation resistance, but because the molecular chain contains a large number of hydrophobic genes or chain links, and has a lot of electrostatic charges, the membrane has a low water permeability and low anti-pollution ability .

(3)膜的污染问题是阻碍超滤技术由实验室研究走向工业应用阶段的最大障碍。在中药制剂的超滤过程中,若药液预处理效果不佳时,膜面易污染,膜孔堵塞,使渗透通量即生产率下降,甚至不能正常工作,生产效率降低,成本上升,导致膜的使用寿命缩短。(3) Membrane fouling is the biggest obstacle preventing ultrafiltration technology from laboratory research to industrial application. In the ultrafiltration process of traditional Chinese medicine preparations, if the pretreatment effect of the liquid medicine is not good, the membrane surface will be easily polluted and the membrane pores will be blocked, which will reduce the permeation flux, that is, the productivity, or even fail to work normally, reduce the production efficiency, and increase the cost, resulting in membrane shortened service life.

(4)膜组件的选择方法尚未建立起来,超滤操作参数尚需优化。影响超滤效果的因素很多,包括膜组件的选择,工艺参数的确定及超滤器使用后的清洗方法等。因此适用于中药体系超滤用的超滤设备及操作工艺,有待进一步研究。(4) The selection method of membrane modules has not been established yet, and the operating parameters of ultrafiltration still need to be optimized. There are many factors that affect the effect of ultrafiltration, including the selection of membrane components, the determination of process parameters and the cleaning method of the ultrafilter after use. Therefore, the ultrafiltration equipment and operating technology suitable for ultrafiltration of traditional Chinese medicine systems need further research.

迄今有关超滤工艺在(复方)丹参制剂中的应用,仅限于报道其用于制备丹参注射液,例如中国人民解放军空军北京医院药局报道了超滤法制备包括复方丹参注射液在内的多种中药注射液(中国人民解放军空军北京医院药局,“超滤法制备复方中药注射液的实验研究”,中草药,1981,12(12):8~12)。四川雅安制药厂郝莉用超滤法(截留分子量20000的超滤膜)制备丹参注射液(郝莉,“超滤法制备丹参注射液的工艺改进”,成都中医药大学学报,1996,27(8):7)。王丹等人报道利用胶团超滤法制备丹参注射液(王丹,“胶团超滤法制备丹参注射液”,中成药,2003,25(6):441~443)。但这些报道均来源于实验室研究,并没有提出工业化生产的可行性及其具体的工艺操作条件。So far, the application of ultrafiltration technology in (compound) Danshen preparations is limited to the report that it is used to prepare Danshen injection. A kind of traditional Chinese medicine injection (Chinese People's Liberation Army Air Force Beijing Hospital Pharmacy, "Experimental Research on Preparation of Compound Chinese Medicine Injection by Ultrafiltration", Chinese Herbal Medicine, 1981, 12(12): 8-12). Hao Li of Sichuan Ya'an Pharmaceutical Factory prepared Danshen Injection by ultrafiltration (ultrafiltration membrane with a molecular weight cut-off of 20,000) (Hao Li, "Technology Improvement for Preparation of Danshen Injection by Ultrafiltration", Journal of Chengdu University of Traditional Chinese Medicine, 1996, 27( 8): 7). Wang Dan et al reported the preparation of Danshen injection by micellar ultrafiltration (Wang Dan, "Preparation of Danshen injection by micellar ultrafiltration", Chinese Patent Medicine, 2003, 25(6): 441-443). However, these reports are all derived from laboratory research, and have not proposed the feasibility of industrial production and its specific process operating conditions.

本发明者经过长期不懈地努力,通过对大量实验数据进行分析,验证了超滤法制备本发明药物的可行性,并确定了合适的工艺操作条件。After long-term and unremitting efforts, the present inventor verified the feasibility of preparing the drug of the present invention by the ultrafiltration method by analyzing a large amount of experimental data, and determined the appropriate process operating conditions.

发明内容Contents of the invention

本发明的目的是提供一种杂质少、有效成分损失小、成本低的超滤法制备工艺制备的治疗冠心病心绞痛的药物,它克服了现有技术的不足,解决了工业化生产超滤工艺条件可操作性的难题。The purpose of the present invention is to provide a medicine for treating coronary heart disease and angina pectoris prepared by an ultrafiltration preparation process with less impurities, less active ingredient loss and low cost. It overcomes the deficiencies in the prior art and solves the industrial production ultrafiltration process conditions operability problem.

本发明是通过下述技术步骤实现的:以丹参、川芎和冰片为原料药,按照以下步骤进行制备:The present invention is realized through the following technical steps: using salvia miltiorrhiza, chuanxiong and borneol as raw materials, it is prepared according to the following steps:

(1)将丹参、川芎混合或分别单独制成水提液或醇提液;(1) Mix Salvia Miltiorrhiza and Rhizoma Chuanxiong or separately make water extract or alcohol extract;

(2)对所述的提取液进行初步澄清处理;(2) Carry out preliminary clarification treatment to described extract;

(3)进一步对所述的提取液进行超滤处理;(3) further carry out ultrafiltration treatment to described extract;

(4)将超滤液浓缩成浸膏,将所得浸膏与冰片及辅料混和均匀后,制成滴丸制剂。(4) Concentrate the ultrafiltrate into an extract, mix the obtained extract with borneol and auxiliary materials evenly, and make a drop pill preparation.

上述原料药的重量百分比为:丹参20%~97%,川芎2%~79%,冰片0.2%~3%;优选为丹参63.0%%~94%,川芎4.0%~35.0%,冰片0.5%~2.0%;更优选为丹参75.2%~90%,川芎9%~23.5%,冰片0.5%~1.3%。丹参、川芎、冰片的重量百分比之和为100%。The weight percentages of the above-mentioned raw materials are: Salvia miltiorrhiza 20%-97%, Chuanxiong 2%-79%, Borneol 0.2%-3%; Preferably Danshen 63.0%-94%, Chuanxiong 4.0%-35.0%, Borneol 0.5%- 2.0%; more preferably 75.2% to 90% of Danshen, 9% to 23.5% of Chuanxiong, and 0.5% to 1.3% of borneol. The sum of the weight percentages of salvia miltiorrhiza, chuanxiong and borneol is 100%.

本发明技术步骤(1)中,醇提液可为不同浓度的低级醇如甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇等的提取液或其混合物的提取液。醇提液可不浓缩或适当浓缩后进行下一步的初步澄清处理。In the technical step (1) of the present invention, the alcohol extract can be lower alcohols of different concentrations such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, etc., or extracts of their mixtures. The alcohol extract can be subjected to the next preliminary clarification treatment without concentration or after proper concentration.

本发明技术步骤(2)中,初步的澄清处理可用一般的材料如纱布、丝绢等进行粗滤,也可用较专业的材料如陶瓷膜进行微滤,也可经高速离心后分取上清液,也可用絮凝剂如壳聚糖絮凝澄清剂、101果汁澄清剂、ZTC1+1天然澄清剂、蛋清絮凝剂等吸附澄清而除去药液中较大的悬浮颗粒,还可用醇沉法除去大部份杂质。既可单用上述澄清方法,也可联合应用,例如粗滤-吸附澄清,吸附澄清-高速离心,粗滤-微滤,粗滤-醇沉等。初步澄清处理的溶液可不浓缩或适当浓缩后进行下一步的超滤;优选不进行浓缩即进行下一步的超滤。In the technical step (2) of the present invention, preliminary clarification treatment can carry out rough filtration with general material such as gauze, silk silk etc., also can carry out microfiltration with more professional material such as ceramic membrane, also can get supernatant after high-speed centrifugation Liquid, also can use flocculant such as chitosan flocculation clarifier, 101 fruit juice clarifier, ZTC1+1 natural clarifier, egg white flocculant etc. Some impurities. The above clarification methods can be used alone or in combination, such as coarse filtration-adsorption clarification, adsorption clarification-high-speed centrifugation, coarse filtration-microfiltration, coarse filtration-alcohol precipitation, etc. The solution that has been preliminarily clarified can be subjected to the next step of ultrafiltration without concentration or after being properly concentrated; preferably, the next step of ultrafiltration is performed without concentration.

本发明技术步骤(3)中,超滤所用的超滤膜可为二醋酸纤维素膜(CA)、三醋酸纤维素膜(CTA)、氰乙基醋酸纤维素膜(CN-CA)、聚砜膜(PS)、磺化聚砜膜(SPS)、聚醚砜膜(PES)、磺化聚醚砜膜(SPES)、聚砜酰胺膜(PSA)、酚酞侧基聚芳砜膜(PDS)、聚偏氟乙烯膜(PVDF)、聚丙烯腈膜(PAN)、聚酰亚胺膜(N)、纤维素膜、甲基丙烯酸甲酯-丙烯腈共聚物膜(MMA-AN)、聚丙烯腈/二醋酸纤维素(PAN/CA)共混膜,动态形成的超滤膜,以及上述膜的改性膜。优选为二醋酸纤维素膜(CA)、三醋酸纤维素膜(CTA)、聚砜膜(PS)、磺化聚砜膜(SPS)、聚醚砜膜(PES)、磺化聚醚砜膜(SPES)、聚砜酰胺膜(PSA),聚偏氟乙烯膜(PVDF)、聚丙烯腈膜(PAN)。In the technical step (3) of the present invention, the ultrafiltration membrane used for ultrafiltration can be cellulose diacetate membrane (CA), cellulose triacetate membrane (CTA), cyanoethyl cellulose acetate membrane (CN-CA), polyester Sulfone membrane (PS), sulfonated polysulfone membrane (SPS), polyethersulfone membrane (PES), sulfonated polyethersulfone membrane (SPES), polysulfone amide membrane (PSA), phenolphthalein side group polyarylsulfone membrane (PDS) ), polyvinylidene fluoride film (PVDF), polyacrylonitrile film (PAN), polyimide film (N), cellulose film, methyl methacrylate-acrylonitrile copolymer film (MMA-AN), poly Acrylonitrile/cellulose diacetate (PAN/CA) blend membranes, dynamically formed ultrafiltration membranes, and modified membranes of the above membranes. Preferably cellulose diacetate membrane (CA), cellulose triacetate membrane (CTA), polysulfone membrane (PS), sulfonated polysulfone membrane (SPS), polyethersulfone membrane (PES), sulfonated polyethersulfone membrane (SPES), polysulfoneamide membrane (PSA), polyvinylidene fluoride membrane (PVDF), polyacrylonitrile membrane (PAN).

上述超滤膜的截留分子量一般为6000~80000,优选为10000~70000,最佳为20000~50000。The molecular weight cut-off of the ultrafiltration membrane is generally 6000-80000, preferably 10000-70000, most preferably 20000-50000.

超滤既可采用错流过滤,也可采用死端过滤,但优选错流过滤。Ultrafiltration can be either cross-flow filtration or dead-end filtration, but cross-flow filtration is preferred.

超滤工艺的操作条件如下:The operating conditions of the ultrafiltration process are as follows:

(1)超滤的进液口压力为0.1~0.5MPa,优选为0.1~0.35Mpa,最佳为0.25~0.35Mpa;超滤的出液口压力比进液口压力低0.5~0.25kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.1~0.2Mpa。(1) The inlet pressure of the ultrafiltration is 0.1-0.5MPa, preferably 0.1-0.35Mpa, and most preferably 0.25-0.35Mpa; the outlet pressure of the ultrafiltration is 0.5-0.25kPa lower than the inlet pressure. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are adopted, and the pressure fluctuation difference is 0.1-0.2Mpa.

(2)料液流速为1.0~4.0m/s,优选为2.0~3.0m/s。超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为1.0~2.0m/s。(2) The flow rate of the feed liquid is 1.0-4.0 m/s, preferably 2.0-3.0 m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating flow or unsteady flow in the membrane channel, and the flow velocity fluctuation difference is 1.0-2.0m/s.

(3)在超滤系统中间歇通入高压惰性气体如氮气,形成气液脉冲流,周期为0.5h~2h通气一次,每次1分钟。(3) In the ultrafiltration system, high-pressure inert gas such as nitrogen is fed intermittently to form a gas-liquid pulse flow, and the cycle is 0.5h-2h to ventilate once, each time for 1 minute.

(3)料液温度为15~50℃,优选为20~40℃。(3) The feed liquid temperature is 15-50°C, preferably 20-40°C.

(4)当料液原液被浓缩1/15~1/5时,再加水或稀醇溶液超滤1~2次;优选为当料液原液被浓缩1/12~1/8时,再加水或稀醇溶液超滤1~2次。(4) When the stock solution is concentrated by 1/15 to 1/5, add water or dilute alcohol solution for ultrafiltration 1 to 2 times; preferably when the stock solution is concentrated by 1/12 to 1/8, add water Or dilute alcohol solution ultrafiltration 1 to 2 times.

(5)料液的PH值控制在5~9,优选为6.0~7.5;(5) The pH value of the feed liquid is controlled at 5 to 9, preferably 6.0 to 7.5;

(6)反冲洗条件:反冲洗压力为0.15~2.5MPa,反冲洗周期为0.5~1.5h、反冲洗时间为1min~10min。当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,一般是工作10~20min,反冲30sec~3min。(6) Backwashing conditions: Backwashing pressure is 0.15-2.5MPa, backwashing cycle is 0.5-1.5h, and backwashing time is 1min-10min. When the ultrafiltration modules are connected in parallel to use the method of alternate backflushing, one or several sets perform normal ultrafiltration and part of the filtrate is flowed out to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a period of time To carry out, generally work for 10 to 20 minutes, and recoil for 30 seconds to 3 minutes.

(7)化学清洗周期为0.5个月~2个月,化学清洗药剂一般为稀酸、稀碱、表面活性剂,优选为稀碱例如0.5%~4.0%氢氧化钠,1.5%氢氧化钠和2%次氯酸钠的混合溶液等,pH值为10~12,清洗工作压力为0.05~1.0MPa。在用化学清洗剂清洗之后,再用水冲洗至近中性。(7) The chemical cleaning cycle is 0.5 months to 2 months. The chemical cleaning agents are generally dilute acids, dilute alkalis, and surfactants, preferably dilute alkalis such as 0.5% to 4.0% sodium hydroxide, 1.5% sodium hydroxide and The mixed solution of 2% sodium hypochlorite, etc., the pH value is 10-12, and the cleaning working pressure is 0.05-1.0MPa. After cleaning with chemical cleaners, rinse with water until nearly neutral.

在超滤过程中,既可单独使用周期性压力波动或者周期性流量波动或者周期性通入惰性气体,也可联合使用,即周期性压力波动和周期性流量波动联合使用,或者周期性压力波动和周期性通入惰性气体联合使用,或者周期性流量波动和周期性通入惰性气体联合使用,或者三者一起联合使用。In the ultrafiltration process, periodic pressure fluctuations or periodic flow fluctuations or periodic inert gas injections can be used alone, or in combination, that is, periodic pressure fluctuations and periodic flow fluctuations are used in combination, or periodic pressure fluctuations It is used in combination with periodic inert gas injection, or in combination with periodic flow fluctuations and inert gas injection, or in combination with the three.

本发明技术步骤(4)中,将超滤液浓缩成浸膏后,与冰片及辅料混和均匀后,加热化料,移入滴丸机的滴罐,药液滴至低温液体石蜡中,除去液体石蜡,选丸。In the technical step (4) of the present invention, after the ultrafiltrate is concentrated into an extractum, after mixing evenly with borneol and auxiliary materials, the chemical material is heated, moved into the dropping tank of the dropping pill machine, and the medicinal liquid is dropped into low-temperature liquid paraffin to remove the liquid Paraffin, choose pills.

其中:辅料为聚乙二醇-6000,其凝点53~58℃,加入量为浸膏与冰片重量的2~6倍;化料温度为60~100℃;液体石蜡的温度为0~10℃(最佳为5~10℃);丸重为5~50mg/粒,直径1.95~4.29mm。Among them: the auxiliary material is polyethylene glycol-6000, its freezing point is 53-58 °C, and the addition amount is 2-6 times the weight of the extract and borneol; the temperature of the chemical material is 60-100 °C; the temperature of the liquid paraffin is 0-10 °C. ℃ (optimally 5-10 ℃); pellet weight 5-50mg/granule, diameter 1.95-4.29mm.

实验例本发明药物治疗冠心病临床观察Experimental example The present invention medicine treats clinical observation of coronary heart disease

1资科与方法1 Materials and methods

1.1一般资料200例冠心病心绞痛患者中,男130例,女70例,年龄35岁~55岁64例,56岁~70岁136例。病程2~6年不等,其中伴有高血压者86例,II型糖尿病7例。所有患者均符合WHO关于缺血性心脏病诊断的命名及标准,其中稳定型心绞痛96例,不稳定型心绞痛104例。随机分为治疗组和对照组,每组100例,两组性别、病史、年龄无明显差异。1.1 General information Among 200 patients with coronary heart disease and angina pectoris, there were 130 males and 70 females, 64 cases aged 35-55 years, and 136 cases aged 56-70 years. The course of the disease ranged from 2 to 6 years, including 86 cases with hypertension and 7 cases with type II diabetes. All patients were in line with WHO's nomenclature and criteria for the diagnosis of ischemic heart disease, including 96 cases of stable angina pectoris and 104 cases of unstable angina pectoris. They were randomly divided into a treatment group and a control group, 100 cases in each group, and there was no significant difference in gender, medical history, and age between the two groups.

1.2给药方法除合并有原发病(高血压、常规用降压药)、糖尿病(常规控制饮食用降糖药)。凡入选病例停用其他治疗冠心病药物。治疗组给予口服本发明药物,每次10粒,每日3次,必要时舌下含服硝酸甘油,疗程28d。对照组给予复方丹参片,每次3片,每日3次,必要时舌下含服硝酸甘油,疗程28d。1.2 Method of administration Except those with primary diseases (hypertension, routinely used antihypertensive drugs), diabetes (routinely used hypoglycemic drugs for diet control). All selected cases stopped using other drugs for the treatment of coronary heart disease. The treatment group was given orally the medicine of the present invention, 10 capsules each time, 3 times a day, and sublingual nitroglycerin was taken if necessary, and the course of treatment was 28 days. The control group was given Compound Danshen Tablets, 3 tablets each time, 3 times a day, and sublingual nitroglycerin if necessary, for 28 days.

1.3观察内容加用本发明药物前后询问临床症状和不良反应。记录血压,做常规12导联心电图,以及血、尿常规及肝肾功能检查。1.3 Observation content Inquire about clinical symptoms and adverse reactions before and after adding the medicine of the present invention. Record blood pressure, do routine 12-lead electrocardiogram, and blood, urine routine and liver and kidney function tests.

1.4疗效评定标准根据中华人民共和国卫生部药政局指定的《心脑血管药物临床研究指导原则》评定。1.4 Efficacy evaluation standards are evaluated in accordance with the "Guiding Principles for Clinical Research of Cardiovascular and Cerebrovascular Drugs" designated by the Pharmaceutical Administration of the Ministry of Health of the People's Republic of China.

1.4.1症状疗效评定标准显效:同等劳动能力不引起心绞痛发生或发作次数减少70%以上,一般活动无胸闷症状;有效:心绞痛发作次数、胸闷症状减轻50%~70%;无效:用药后以上情况无明显变化。1.4.1 Symptom efficacy evaluation criteria Significantly effective: the same labor capacity does not cause the occurrence of angina pectoris or the number of attacks is reduced by more than 70%, and there is no chest tightness in general activities; effective: the number of angina pectoris and chest tightness are reduced by 50% to 70%; invalid: more than 70% after medication The situation has not changed significantly.

1.4.2心电图疗效评定标准显效:静息心电图缺血表现恢复正常;有效:静息心电图缺血性ST段下降,治疗后回升1mm以上,但未正常,下壁及左胸导联倒置,T波变浅达1mm组.无效:静息心电图与治疗前基本相同.1.4.2 ECG curative effect evaluation criteria Markedly effective: resting ECG ischemic manifestations return to normal; effective: resting ECG ischemic ST-segment decline, after treatment, the recovery is more than 1 mm, but not normal, the inferior wall and left chest leads are inverted, T The wave became shallower up to 1mm group. Invalid: the resting electrocardiogram was basically the same as before treatment.

2结果2 results

2.1治疗组与对照组疗效比较(见表I、表II)。2.1 Comparison of curative effect between the treatment group and the control group (see Table I, Table II).

表I心绞痛症状疗效比较Table 1 Angina pectoris symptom curative effect comparison

Figure G2004100729272D00061
Figure G2004100729272D00061

表II心电图疗效对比Table II ECG curative effect comparison

Figure G2004100729272D00062
Figure G2004100729272D00062

具体实施方式Detailed ways

以下结合实施例对本发明作进一步的阐述。这些实施例仅用于例举的目的,而不是以任何方式限制本发明。The present invention will be further elaborated below in conjunction with embodiment. These examples are for illustrative purposes only and do not limit the invention in any way.

实施例一Embodiment one

原料药采用丹参55.8g、川芎3.4g、冰片0.8g。The raw materials are 55.8g of Danshen, 3.4g of Chuanxiong, and 0.8g of borneol.

用乙醇提取丹参和川芎,得到丹参和川芎的乙醇提取液,用纱布将此提取液过滤,收集滤液。滤液用截留分子量为6000的二醋酸纤维素膜进行超滤,过滤方式采用错流过滤。超滤工艺的操作条件为:超滤的进液口压力为0.1Mpa,超滤的出液口压力比进液口压力低0.5kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.1Mpa。料液流速为1.0m/s,超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为1.0m/s,在超滤系统中间歇通入氮气,形成气液脉冲流,周期为0.5h通气一次,每次1分钟。料液温度为15℃,当料液原液被浓缩1/15时,再加水或稀醇溶液超滤1次,料液的PH值控制在5。反冲洗压力为0.15MPa,反冲洗周期为0.5h、反冲洗时间为1min。当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,工作10min,反冲30sec。化学清洗周期为0.5月,化学清洗药剂为0.5%~4.0%氢氧化钠、1.5%氢氧化钠和2%次氯酸钠的混合溶液,pH值为10~12,清洗工作压力为0.05MPa。在用化学清洗剂清洗之后,再用水冲洗至近中性。Extract Danshen and Chuanxiong with ethanol to obtain ethanol extracts of Danshen and Chuanxiong, filter the extract with gauze, and collect the filtrate. The filtrate was ultrafiltered with a cellulose diacetate membrane with a molecular weight cut-off of 6000, and the filtration method was cross-flow filtration. The operating conditions of the ultrafiltration process are: the pressure of the liquid inlet of the ultrafiltration is 0.1Mpa, and the pressure of the liquid outlet of the ultrafiltration is 0.5kPa lower than the pressure of the liquid inlet. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are used, and the pressure fluctuation difference is 0.1Mpa. The flow rate of the feed liquid is 1.0m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating flow or unstable flow in the membrane channel. The difference in flow rate fluctuations is 1.0m/s. Nitrogen is intermittently fed into the ultrafiltration system , to form a gas-liquid pulse flow, and the period is 0.5h to ventilate once, each time for 1 minute. The temperature of the feed liquid is 15°C. When the original feed liquid is concentrated by 1/15, add water or dilute alcohol solution for ultrafiltration once, and the pH value of the feed liquid is controlled at 5. The backwash pressure is 0.15MPa, the backwash cycle is 0.5h, and the backwash time is 1min. When the ultrafiltration modules are connected in parallel to use the method of alternate backflushing, one or several sets perform normal ultrafiltration and part of the filtrate is flowed out to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a period of time Carry out, work for 10min, recoil for 30sec. The chemical cleaning cycle is 0.5 months, the chemical cleaning agent is a mixed solution of 0.5%-4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, the pH value is 10-12, and the cleaning working pressure is 0.05MPa. After cleaning with chemical cleaners, rinse with water until nearly neutral.

将所述的超滤液浓缩得到相对密度为1.35~1.39(55℃)的浸膏。取浸膏和冰片,与聚乙二醇-600018g混和均匀,加热至温度85℃,化料20~120分钟后,移至罐温保持在85~90℃的滴丸机滴罐中。药液滴至7~8℃液体石蜡中,取出滴丸,除油,筛网选丸,制成1000粒滴丸,即得。Concentrating the ultrafiltrate to obtain an extract with a relative density of 1.35-1.39 (55° C.). Take the extract and borneol, mix evenly with polyethylene glycol-6000018g, heat to a temperature of 85°C, and after 20-120 minutes to make the material, move it to a dropping tank of a dripping machine whose tank temperature is kept at 85-90°C. Drop the drug solution into liquid paraffin at 7-8°C, take out the dropping pills, remove the oil, select the pills through a sieve, and make 1000 dropping pills.

实施例二Embodiment two

原料药采用丹参59.3g、川芎6.38g、冰片0.34g。The raw materials are 59.3g of Danshen, 6.38g of Chuanxiong, and 0.34g of borneol.

将粗粉碎的丹参加5倍量水,煎煮2小时,滤过,滤渣进行第二次提取,加入4倍量水,煎1小时,滤过,滤渣弃去,合并滤液,得丹参提取液。用70%乙醇提取川芎,得川芎提取液。将上述丹参提取液和川芎提取液合并,静置,滤过。滤液用截留分子量为80000的聚砜膜进行超滤,过滤方式采用死端过滤。超滤工艺的操作条件为:超滤的进液口压力为0.5Mpa,超滤的出液口压力比进液口压力低0.25kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.2Mpa。料液流速为4.0m/s,超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为2.0m/s,在超滤系统中间歇通入氮气,形成气液脉冲流,周期为2h通气一次,每次1分钟。料液温度为50℃,当料液原液被浓缩1/5时,再加水或稀醇溶液超滤2次,料液的PH值控制在9。反冲洗压力为2.5MPa,反冲洗周期为1.5h、反冲洗时间为10min。当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,工作20min,反冲3min。化学清洗周期为2个月,化学清洗药剂为0.5%~4.0%氢氧化钠、1.5%氢氧化钠和2%次氯酸钠的混合溶液,pH值为10~12,清洗工作压力为1.0MPa。在用化学清洗剂清洗之后,再用水冲洗至近中性。Decoct the coarsely crushed Salvia miltiorrhiza in 5 times the amount of water for 2 hours, filter, and extract the filter residue for the second time, add 4 times the amount of water, fry for 1 hour, filter, discard the filter residue, and combine the filtrates to obtain the salvia miltiorrhiza extract . Extract Rhizoma Chuanxiong with 70% ethanol to obtain Ligusticum Chuanxiong extract. The above-mentioned Danshen extract and Chuanxiong extract were combined, allowed to stand, and filtered. The filtrate was ultrafiltered with a polysulfone membrane with a molecular weight cut-off of 80,000, and the filtration method was dead-end filtration. The operating conditions of the ultrafiltration process are: the pressure of the liquid inlet of the ultrafiltration is 0.5Mpa, and the pressure of the liquid outlet of the ultrafiltration is 0.25kPa lower than the pressure of the liquid inlet. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are adopted, and the pressure fluctuation difference is 0.2Mpa. The flow rate of the feed liquid is 4.0m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating flow or unstable flow in the membrane channel. The difference in flow rate fluctuations is 2.0m/s. Nitrogen is intermittently fed into the ultrafiltration system , to form a gas-liquid pulse flow, and the period is 2h to ventilate once, each time for 1 minute. The temperature of the feed liquid is 50°C. When the raw liquid of the feed liquid is concentrated by 1/5, add water or dilute alcohol solution for ultrafiltration twice, and the pH value of the feed liquid is controlled at 9. The backwash pressure is 2.5MPa, the backwash cycle is 1.5h, and the backwash time is 10min. When the ultrafiltration modules are connected in parallel to use the method of alternate backflushing, one or several sets perform normal ultrafiltration and part of the filtrate is flowed out to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a period of time Carry out, work for 20 minutes, recoil for 3 minutes. The chemical cleaning cycle is 2 months, the chemical cleaning agent is a mixed solution of 0.5% to 4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, the pH value is 10 to 12, and the cleaning working pressure is 1.0MPa. After cleaning with chemical cleaners, rinse with water until nearly neutral.

将所述的超滤液浓缩得到相对密度为1.35~1.39(55℃)的浸膏。取浸膏和冰片,与聚乙二醇-600020g混和均匀,加热至温度85℃,化料20~120分钟后,移至罐温保持在85~90℃的滴丸机滴罐中。药液滴至7~8℃液体石蜡中,取出滴丸,除油,筛网选丸,制成1000粒滴丸,即得。Concentrating the ultrafiltrate to obtain an extract with a relative density of 1.35-1.39 (55° C.). Take the extract and borneol, mix evenly with 20g of polyethylene glycol-6000, heat to a temperature of 85°C, and after 20-120 minutes of compounding, move to a dropping tank of a dripping machine whose tank temperature is kept at 85-90°C. Drop the drug solution into liquid paraffin at 7-8°C, take out the dropping pills, remove the oil, select the pills through a sieve, and make 1000 dropping pills.

实施例三Embodiment three

原料药采用丹参36.0g、川芎23.2g、冰片0.8g。The raw materials are 36.0g of Danshen, 23.2g of Chuanxiong, and 0.8g of borneol.

用80%乙醇提取丹参和川芎,得到丹参和川芎的乙醇提取液,将此提取液高速离心后分取上清液。将此液体用截留分子量为50000的聚砜膜进行超滤,过滤方式采用错流过滤。超滤工艺的操作条件为:超滤的进液口压力为0.35Mpa,超滤的出液口压力比进液口压力低0.20kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.2Mpa。料液流速为3.0m/s,超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为2.0m/s,在超滤系统中间歇通入氮气,形成气液脉冲流,周期为2h通气一次,每次1分钟。料液温度为40℃,当料液原液被浓缩1/8时,再加水或稀醇溶液超滤2次,料液的PH值控制在7.5。反冲洗压力为2.5MPa,反冲洗周期为1.5h、反冲洗时间为10min。当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,工作20min,反冲3min。化学清洗周期为2个月,化学清洗药剂为0.5%~4.0%氢氧化钠、1.5%氢氧化钠和2%次氯酸钠的混合溶液,pH值为10~12,清洗工作压力为1.0MPa。在用化学清洗剂清洗之后,再用水冲洗至近中性。Extracting Danshen and Chuanxiong with 80% ethanol to obtain ethanol extracts of Danshen and Chuanxiong, centrifuging the extract at high speed and separating supernatant. The liquid is ultrafiltered with a polysulfone membrane with a molecular weight cut-off of 50,000, and the filtration method adopts cross-flow filtration. The operating conditions of the ultrafiltration process are: the pressure of the liquid inlet of the ultrafiltration is 0.35Mpa, and the pressure of the liquid outlet of the ultrafiltration is 0.20kPa lower than the pressure of the liquid inlet. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are adopted, and the pressure fluctuation difference is 0.2Mpa. The flow rate of the feed liquid is 3.0m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating or unstable flows in the membrane channel. The difference in flow rate fluctuations is 2.0m/s. Nitrogen is intermittently fed into the ultrafiltration system , to form a gas-liquid pulse flow, and the period is 2h to ventilate once, each time for 1 minute. The temperature of the feed liquid is 40°C. When the original feed liquid is concentrated by 1/8, add water or dilute alcohol solution for ultrafiltration twice, and the pH value of the feed liquid is controlled at 7.5. The backwash pressure is 2.5MPa, the backwash cycle is 1.5h, and the backwash time is 10min. When the ultrafiltration modules are connected in parallel to use the method of alternate backflushing, one or several sets perform normal ultrafiltration and part of the filtrate is flowed out to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a period of time Carry out, work for 20 minutes, recoil for 3 minutes. The chemical cleaning cycle is 2 months, the chemical cleaning agent is a mixed solution of 0.5% to 4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, the pH value is 10 to 12, and the cleaning working pressure is 1.0MPa. After cleaning with chemical cleaners, rinse with water until nearly neutral.

将所述的超滤液浓缩得到相对密度为1.35~1.39(55℃)的浸膏。取浸膏和冰片,与聚乙二醇-6000 20g混和均匀,加热至温度60℃,化料20~120分钟后,移至罐温保持在90℃的滴丸机滴罐中.药液滴至7~8℃甲基硅油中,取出滴丸,除油,筛网选丸,制成1000粒滴丸,即得.Concentrating the ultrafiltrate to obtain an extract with a relative density of 1.35-1.39 (55° C.). Take the extract and borneol, mix evenly with 20g of polyethylene glycol-6000, heat to a temperature of 60°C, and after 20 to 120 minutes, transfer to a dropping tank of a dripping machine with a tank temperature of 90°C. Put it in methyl silicone oil at 7-8°C, take out the dripping pills, remove the oil, select the pills with a screen, and make 1000 dropping pills, that is.

实施例四Embodiment four

原料药采用丹参41.1g、川芎8.0g、冰片0.46g。The raw materials are 41.1g of Salvia miltiorrhiza, 8.0g of Chuanxiong, and 0.46g of borneol.

将粗粉碎的丹参、川芎药材至提取罐中,加5倍量水,煎煮2小时,滤过,滤渣进行第二次提取,加入4倍量水,煎1小时,滤过,滤渣弃去,合并滤液。滤液用截留分子量为6000的二醋酸纤维素膜进行超滤,过滤方式采用错流过滤。超滤工艺的操作条件为:超滤的进液口压力为0.1Mpa,超滤的出液口压力比进液口压力低0.5kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.1Mpa。料液流速为1.0m/s,超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为1.0m/s,在超滤系统中间歇通入氮气,形成气液脉冲流,周期为0.5h通气一次,每次1分钟。料液温度为15℃,当料液原液被浓缩1/15时,再加水或稀醇溶液超滤1次,料液的PH值控制在5。反冲洗压力为0.15MPa,反冲洗周期为0.5h、反冲洗时间为1min。当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,工作10min,反冲30sec。化学清洗周期为0.5月,化学清洗药剂为0.5%~4.0%氢氧化钠、1.5%氢氧化钠和2%次氯酸钠的混合溶液,pH值为10~12,清洗工作压力为0.05MPa。在用化学清洗剂清洗之后,再用水冲洗至近中性。Put the coarsely crushed Danshen and Chuanxiong herbs into the extraction tank, add 5 times the amount of water, decoct for 2 hours, filter, and extract the filter residue for the second time, add 4 times the amount of water, fry for 1 hour, filter, and discard the filter residue , combined filtrate. The filtrate was ultrafiltered with a cellulose diacetate membrane with a molecular weight cut-off of 6000, and the filtration method was cross-flow filtration. The operating conditions of the ultrafiltration process are: the pressure of the liquid inlet of the ultrafiltration is 0.1Mpa, and the pressure of the liquid outlet of the ultrafiltration is 0.5kPa lower than the pressure of the liquid inlet. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are used, and the pressure fluctuation difference is 0.1Mpa. The flow rate of the feed liquid is 1.0m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating flow or unstable flow in the membrane channel. The difference in flow rate fluctuations is 1.0m/s. Nitrogen is intermittently fed into the ultrafiltration system , to form a gas-liquid pulse flow, and the period is 0.5h to ventilate once, each time for 1 minute. The temperature of the feed liquid is 15°C. When the original feed liquid is concentrated by 1/15, add water or dilute alcohol solution for ultrafiltration once, and the pH value of the feed liquid is controlled at 5. The backwash pressure is 0.15MPa, the backwash cycle is 0.5h, and the backwash time is 1min. When the ultrafiltration modules are connected in parallel to use the method of alternate backflushing, one or several sets perform normal ultrafiltration and part of the filtrate is flowed out to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a period of time Carry out, work for 10min, recoil for 30sec. The chemical cleaning cycle is 0.5 months, the chemical cleaning agent is a mixed solution of 0.5%-4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, the pH value is 10-12, and the cleaning working pressure is 0.05MPa. After cleaning with chemical cleaners, rinse with water until nearly neutral.

将所述的超滤液浓缩得到相对密度为1.35~1.39(55℃)的浸膏。取浸膏和冰片,与聚乙二醇-6000 21g混和均匀,加热至温度60℃,化料20~120分钟后,移至罐温保持在90℃的滴丸机滴罐中。药液滴至7~8℃液体石蜡中,取出滴丸,除油,筛网选丸,制成1000粒滴丸,即得。Concentrating the ultrafiltrate to obtain an extract with a relative density of 1.35-1.39 (55° C.). Take the extract and borneol, mix evenly with 21g of polyethylene glycol-6000, heat to a temperature of 60°C, and after 20 to 120 minutes of compounding, move to a dropping tank of a dropping pill machine whose tank temperature is kept at 90°C. Drop the drug solution into liquid paraffin at 7-8°C, take out the dropping pills, remove the oil, select the pills through a sieve, and make 1000 dropping pills.

实施例五Embodiment five

原料药采用丹参29.0g、川芎30.6g、冰片0.6g。The raw materials are 29.0g of Salvia miltiorrhiza, 30.6g of Chuanxiong, and 0.6g of borneol.

将粗粉碎的丹参、川芎药材至提取罐中,加5倍量水,煎煮2小时,滤过,滤渣进行第二次提取,加入4倍量水,煎1小时,滤过,滤渣弃去,合并滤液。滤液用截留分子量为80000的聚砜膜进行超滤,过滤方式采用死端过滤。超滤工艺的操作条件为:超滤的进液口压力为0.5Mpa,超滤的出液口压力比进液口压力低0.25kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.2Mpa。料液流速为4.0m/s,超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为2.0m/s,在超滤系统中间歇通入氮气,形成气液脉冲流,周期为2h通气一次,每次1分钟。料液温度为50℃,当料液原液被浓缩1/5时,再加水或稀醇溶液超滤2次,料液的PH值控制在9。反冲洗压力为2.5MPa,反冲洗周期为1.5h、反冲洗时间为10min。当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,工作20min,反冲3min。化学清洗周期为2个月,化学清洗药剂为0.5%~4.0%氢氧化钠、1.5%氢氧化钠和2%次氯酸钠的混合溶液,pH值为10~12,清洗工作压力为1.0MPa。在用化学清洗剂清洗之后,再用水冲洗至近中性。Put the coarsely crushed Danshen and Chuanxiong herbs into the extraction tank, add 5 times the amount of water, decoct for 2 hours, filter, and extract the filter residue for the second time, add 4 times the amount of water, fry for 1 hour, filter, and discard the filter residue , combined filtrate. The filtrate was ultrafiltered with a polysulfone membrane with a molecular weight cut-off of 80,000, and the filtration method was dead-end filtration. The operating conditions of the ultrafiltration process are: the pressure of the liquid inlet of the ultrafiltration is 0.5Mpa, and the pressure of the liquid outlet of the ultrafiltration is 0.25kPa lower than the pressure of the liquid inlet. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are adopted, and the pressure fluctuation difference is 0.2Mpa. The flow rate of the feed liquid is 4.0m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating flow or unstable flow in the membrane channel. The difference in flow rate fluctuations is 2.0m/s. Nitrogen is intermittently fed into the ultrafiltration system , to form a gas-liquid pulse flow, and the period is 2h to ventilate once, each time for 1 minute. The temperature of the feed liquid is 50°C. When the raw liquid of the feed liquid is concentrated by 1/5, add water or dilute alcohol solution for ultrafiltration twice, and the pH value of the feed liquid is controlled at 9. The backwash pressure is 2.5MPa, the backwash cycle is 1.5h, and the backwash time is 10min. When the ultrafiltration modules are connected in parallel to use the method of alternate backflushing, one or several sets perform normal ultrafiltration and part of the filtrate is flowed out to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a period of time Carry out, work for 20 minutes, recoil for 3 minutes. The chemical cleaning cycle is 2 months, the chemical cleaning agent is a mixed solution of 0.5% to 4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, the pH value is 10 to 12, and the cleaning working pressure is 1.0MPa. After cleaning with chemical cleaners, rinse with water until nearly neutral.

将所述的超滤液浓缩得到相对密度为1.32~1.40(55℃)的浸膏,取浸膏和冰片,与聚乙二醇-6000 20g混和均匀,加热至温度60℃,化料20~120分钟后,移至罐温保持在90℃的滴丸机滴罐中.药液滴至7~8℃液体石蜡中,取出滴丸,除油,筛网选丸,制成1000粒滴丸,即得.Concentrate the ultrafiltrate to obtain an extract with a relative density of 1.32 to 1.40 (55° C.), take the extract and borneol, mix with 20 g of polyethylene glycol-6000, heat to a temperature of 60° C. After 120 minutes, move to the dripping tank of the dropping pill machine with the tank temperature kept at 90°C. Drop the drug liquid into the liquid paraffin at 7-8°C, take out the dropping pills, remove the oil, and select the pills with a screen to make 1000 dropping pills , that is.

实施例六Embodiment six

原料药采用丹参21.0g、川芎38.0g、冰片0.4g。The raw materials are 21.0g of Danshen, 38.0g of Chuanxiong, and 0.4g of borneol.

取经粗粉碎的丹参、川芎药材至提取罐中,加入0.89g碳酸氢钠,加4倍量水,煎煮2小时,滤过,滤渣进行第二次提取,加入4倍量水,煎煮1小时,滤过,滤渣弃去,合并滤液。滤液用截留分子量为50000的聚砜膜进行超滤,过滤方式采用错流过滤。超滤工艺的操作条件为:超滤的进液口压力为0.35Mpa,超滤的出液口压力比进液口压力低0.20kPa。超滤初期采用较低压力,然后慢慢升压;在超滤过程中,采用周期性压力波动,压力波动差为0.2Mpa。料液流速为3.0m/s,超滤过程中,采用周期性流量波动以便在膜通道内产生脉动流或不稳定流,流速波动差为2.0m/s,在超滤系统中间歇通入氮气,形成气液脉冲流,周期为2h通气一次,每次1分钟。料液温度为40℃,当料液原液被浓缩1/8时,再加水或稀醇溶液超滤2次,料液的PH值控制在7.5。反冲洗压力为2.5MPa,反冲洗周期为1.5h、反冲洗时间为10min。当将超滤组件并联使用交替反冲的方法时,其中一套或几套进行正常的超滤并分流出一部分滤液来反冲另一套或几套组件的超滤膜,间隔一段时间后交换进行,工作20min,反冲3min。化学清洗周期为2个月,化学清洗药剂为0.5%~4.0%氢氧化钠、1.5%氢氧化钠和2%次氯酸钠的混合溶液,pH值为10~12,清洗工作压力为1.0MPa。在用化学清洗剂清洗之后,再用水冲洗至近中性。Take the coarsely crushed medicinal materials of Salvia miltiorrhiza and Chuanxiong into the extraction tank, add 0.89g of sodium bicarbonate, add 4 times the amount of water, decoct for 2 hours, filter, and extract the filter residue for the second time, add 4 times the amount of water, decoct for 1 hours, filtered, the filter residue was discarded, and the filtrates were combined. The filtrate was ultrafiltered with a polysulfone membrane with a molecular weight cut-off of 50,000, and the filtration method was cross-flow filtration. The operating conditions of the ultrafiltration process are: the pressure of the liquid inlet of the ultrafiltration is 0.35Mpa, and the pressure of the liquid outlet of the ultrafiltration is 0.20kPa lower than the pressure of the liquid inlet. In the initial stage of ultrafiltration, a lower pressure is used, and then the pressure is gradually increased; in the process of ultrafiltration, periodic pressure fluctuations are adopted, and the pressure fluctuation difference is 0.2Mpa. The flow rate of the feed liquid is 3.0m/s. During the ultrafiltration process, periodic flow fluctuations are used to generate pulsating or unstable flows in the membrane channel. The difference in flow rate fluctuations is 2.0m/s. Nitrogen is intermittently fed into the ultrafiltration system , to form a gas-liquid pulse flow, and the period is 2h to ventilate once, each time for 1 minute. The temperature of the feed liquid is 40°C. When the original feed liquid is concentrated by 1/8, add water or dilute alcohol solution for ultrafiltration twice, and the pH value of the feed liquid is controlled at 7.5. The backwash pressure is 2.5MPa, the backwash cycle is 1.5h, and the backwash time is 10min. When the ultrafiltration modules are connected in parallel to use the method of alternate backflushing, one or several sets perform normal ultrafiltration and part of the filtrate is flowed out to backwash the ultrafiltration membrane of another set or several sets of components, and exchange after a period of time Carry out, work for 20 minutes, recoil for 3 minutes. The chemical cleaning cycle is 2 months, the chemical cleaning agent is a mixed solution of 0.5% to 4.0% sodium hydroxide, 1.5% sodium hydroxide and 2% sodium hypochlorite, the pH value is 10 to 12, and the cleaning working pressure is 1.0MPa. After cleaning with chemical cleaners, rinse with water until nearly neutral.

将所述的超滤液浓缩得到相对密度为1.32~1.40(55℃)的浸膏,取浸膏和冰片,与聚乙二醇-6000 18g混和均匀,加热至温度85℃,化料20~120分钟后,移至罐温保持在85~90℃的滴丸机滴罐中。药液滴至7~8℃液体石蜡中,取出滴丸,除油,筛网选丸,制成1000粒滴丸,即得。Concentrate the ultrafiltrate to obtain an extract with a relative density of 1.32 to 1.40 (55° C.), take the extract and borneol, mix it with polyethylene glycol-6000 18 g, heat to a temperature of 85° C. After 120 minutes, move to the dropping tank of the dropping pill machine whose tank temperature is kept at 85-90°C. Drop the drug solution into liquid paraffin at 7-8°C, take out the dropping pills, remove the oil, select the pills through a sieve, and make 1000 dropping pills.

Claims (12)

1.一种治疗冠心病心绞痛的中药滴丸,它以丹参、川芎和冰片为原料药制成,其特征在于,所述的原料药的重量百分配比为:丹参20%~97%,川芎2%~79%,冰片0.2%~3%;1. a Chinese medicine dripping pill for the treatment of coronary heart disease angina pectoris, it is made with salvia miltiorrhiza, Rhizoma Chuanxiong and Borneolum as raw materials, it is characterized in that, the weight percent ratio of described raw materials is: 20%~97% of salvia miltiorrhiza, 20%~97% of chuanxiong 2%~79%, borneol 0.2%~3%; 其制备的工艺步骤为:The process steps of its preparation are: (1)将丹参、川芎混合或单独制成水提液或醇提液;(1) Mix Salvia Miltiorrhiza and Rhizoma Chuanxiong or make water extract or alcohol extract separately; (2)对所述的提取液进行初步澄清处理;(2) Carry out preliminary clarification treatment to described extract; (3)进一步对所述的提取液进行超滤处理;(3) further carry out ultrafiltration treatment to described extract; (4)将超滤液浓缩,将所得浸膏与冰片及辅料混和均匀后,制成滴丸;(4) Concentrate the ultrafiltrate, mix the obtained extract with borneol and auxiliary materials, and make dropping pills; 所述超滤处理的操作工艺条件如下:The operation process condition of described ultrafiltration treatment is as follows: 超滤的进液口压力为0.1~0.5MPa,超滤的出液口压力比进液口压力低0.25~0.5kPa;料液温度为15~50℃;料液的pH值控制在5~9;当料液原液被浓缩1/15~1/5时,再加水或稀醇溶液超滤1~2次。The liquid inlet pressure of ultrafiltration is 0.1-0.5MPa, and the liquid outlet pressure of ultrafiltration is 0.25-0.5kPa lower than the liquid inlet pressure; the temperature of the feed liquid is 15-50°C; the pH value of the feed liquid is controlled at 5-9 ; When the stock solution is concentrated by 1/15 to 1/5, add water or dilute alcohol solution for ultrafiltration 1 or 2 times. 2.根据权利要求1所述的中药滴丸,其特征在于,所述的原料的重量百分比为:2. Chinese medicine dripping pill according to claim 1, is characterized in that, the weight percentage of described raw material is: 丹参63.0%~94%,Salvia miltiorrhiza 63.0%~94%, 川芎4.0%~35.0%,Chuanxiong 4.0%~35.0%, 冰片0.5%~2.0%。Borneol 0.5% ~ 2.0%. 3.根据权利要求2所述的中药滴丸,其特征在于,所述的原料的重量百分比为:3. Chinese medicine dripping pill according to claim 2, is characterized in that, the weight percent of described raw material is: 丹参75.2%~90%,Danshen 75.2% ~ 90%, 川芎9%~23.5%,Chuanxiong 9%~23.5%, 冰片0.5%~1.3%。Borneol 0.5% ~ 1.3%. 4.根据权利要求1~3任一所述的中药滴丸,其特征在于,所述的醇提液为选自以下的低级醇或其混合物的提取液:甲醇、乙醇、正丙醇、异丙醇、正丁醇、异丁醇。4. according to the arbitrary described Chinese medicine dripping pill of claim 1~3, it is characterized in that, described ethanol extract is the extract that is selected from following lower alcohol or its mixture: methanol, ethanol, n-propanol, isopropanol, Propanol, n-butanol, isobutanol. 5.根据权利要求1~3任一所述的中药滴丸,其特征在所述的醇提液为乙醇提取液。5. The Chinese medicine dripping pill according to any one of claims 1 to 3, characterized in that the alcohol extract is an ethanol extract. 6.根据权利要求1~3任一所述的中药滴丸,其特征在于,所述步骤(1)得到的是丹参和川芎混合制成的乙醇提取液。6. The Chinese medicine dripping pill according to any one of claims 1 to 3, characterized in that, what is obtained in the step (1) is an ethanol extract prepared by mixing Salvia miltiorrhiza and Rhizoma Chuanxiong. 7.根据权利要求1~3任一所述的中药滴丸,其特征在于,所述步骤(1)得到的是丹参和川芎混合制成的水提取液。7. The Chinese medicine dripping pill according to any one of claims 1 to 3, characterized in that, what is obtained in the step (1) is a water extract prepared by mixing Salvia miltiorrhiza and Rhizoma Chuanxiong. 8.根据权利要求1~3任一所述的中药滴丸,其特征在于,所述步骤(1)为:取经粗粉碎的丹参、川芎药材至提取罐中,加入适量碳酸氢钠,加水煎煮二次,滤过,滤渣弃去,合并滤液,得提取液。8. According to the Chinese medicine dripping pill described in any one of claims 1 to 3, it is characterized in that the step (1) is: take the coarsely crushed medicinal materials of Salvia Miltiorrhiza and Rhizoma Chuanxiong into the extraction tank, add appropriate amount of sodium bicarbonate, add water to decoct Boil twice, filter, discard the filter residue, combine the filtrate to obtain the extract. 9.根据权利要求1~3任一所述的中药滴丸,其特征在于于,所述的初步澄清处理为粗滤-吸附澄清、吸附澄清-高速离心、粗滤-微滤或粗滤-醇沉。9. The Chinese medicine dripping pill according to any one of claims 1 to 3, characterized in that, the preliminary clarification treatment is coarse filtration-adsorption clarification, adsorption clarification-high-speed centrifugation, coarse filtration-microfiltration or coarse filtration- Alcoholic. 10.根据权利要求1~3任一所述的中药滴丸,其特征在于,所述超滤处理所用的超滤膜选自:二醋酸纤维素膜、三醋酸纤维素膜、氰乙基醋酸纤维素膜、聚砜膜、磺化聚砜膜、聚醚砜膜、磺化聚醚砜膜、聚砜酰胺膜、酚酞侧基聚芳砜膜、聚偏氟乙烯膜、聚丙烯腈膜、聚酰亚胺膜、纤维素膜、甲基丙烯酸甲酯-丙烯腈共聚物膜、聚丙烯腈/二醋酸纤维素共混膜,动态形成的超滤膜,以及上述膜的改性膜;其超滤膜的截留分子量为6000~80000。10. according to the arbitrary described Chinese medicine dripping pill of claim 1~3, it is characterized in that, the used ultrafiltration membrane of described ultrafiltration treatment is selected from: cellulose diacetate film, cellulose triacetate film, cyanoethyl acetic acid Cellulose membrane, polysulfone membrane, sulfonated polysulfone membrane, polyethersulfone membrane, sulfonated polyethersulfone membrane, polysulfone amide membrane, polyarylsulfone membrane with phenolphthalein side group, polyvinylidene fluoride membrane, polyacrylonitrile membrane, Polyimide membranes, cellulose membranes, methyl methacrylate-acrylonitrile copolymer membranes, polyacrylonitrile/cellulose diacetate blend membranes, dynamically formed ultrafiltration membranes, and modified membranes of the above membranes; The molecular weight cut-off of the ultrafiltration membrane is 6000-80000. 11.根据权利要求10所述的中药滴丸,其特征在于,所述超滤膜选自:二醋酸纤维素膜、三醋酸纤维素膜、聚砜膜、磺化聚砜膜、聚醚砜膜、磺化聚醚砜膜、聚砜酰胺膜,聚偏氟乙烯膜、聚丙烯腈膜;其超滤膜的截留分子量为10000~70000.11. The Chinese medicine dripping pill according to claim 10, wherein the ultrafiltration membrane is selected from: cellulose diacetate membrane, cellulose triacetate membrane, polysulfone membrane, sulfonated polysulfone membrane, polyethersulfone Membrane, sulfonated polyethersulfone membrane, polysulfoneamide membrane, polyvinylidene fluoride membrane, polyacrylonitrile membrane; the molecular weight cut-off of the ultrafiltration membrane is 10000-70000. 12.根据权利要求1所述的中药滴丸,其特征在于,在所述超滤的过程中单独或者联合采用下述方法:周期性压力波动、周期性流量波动、间歇地通入惰性气体;其中周期性压力波动的压力波动差为0.1~0.2Mpa,周期性流量波动的流速波动差为1.0~2.0米/秒,间歇地通入惰性气体为0.5小时~2小时通气一次,每次1分钟。12. The Chinese medicine dripping pill according to claim 1, characterized in that, in the process of the ultrafiltration, the following methods are adopted alone or in combination: periodic pressure fluctuations, periodic flow fluctuations, intermittently feeding inert gas; Among them, the pressure fluctuation difference of the periodic pressure fluctuation is 0.1-0.2Mpa, the flow velocity fluctuation difference of the periodic flow fluctuation is 1.0-2.0 m/s, and the inert gas is intermittently injected once every 0.5-2 hours, each time for 1 minute .
CN 200410072927 2004-11-26 2004-11-26 Chinese Medicine Dropping Pills for Treating Angina Pectoris of Coronary Heart Disease Expired - Lifetime CN1778334B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200410072927 CN1778334B (en) 2004-11-26 2004-11-26 Chinese Medicine Dropping Pills for Treating Angina Pectoris of Coronary Heart Disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200410072927 CN1778334B (en) 2004-11-26 2004-11-26 Chinese Medicine Dropping Pills for Treating Angina Pectoris of Coronary Heart Disease

Publications (2)

Publication Number Publication Date
CN1778334A CN1778334A (en) 2006-05-31
CN1778334B true CN1778334B (en) 2010-05-12

Family

ID=36768871

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200410072927 Expired - Lifetime CN1778334B (en) 2004-11-26 2004-11-26 Chinese Medicine Dropping Pills for Treating Angina Pectoris of Coronary Heart Disease

Country Status (1)

Country Link
CN (1) CN1778334B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101085027B (en) * 2006-06-08 2011-09-21 天津天士力制药股份有限公司 Traditional Chinese medicinal composition containing red sage root and kudzuvine root and its preparation
CN102579572B (en) * 2012-02-17 2014-04-02 李晓云 Heart resurrection dripping pill production process

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1348815A (en) * 2001-11-09 2002-05-15 天津天士力制药股份有限公司 Medicine for preventing and treating coronary heart disease and angina pectoris and its prepn and other use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1348815A (en) * 2001-11-09 2002-05-15 天津天士力制药股份有限公司 Medicine for preventing and treating coronary heart disease and angina pectoris and its prepn and other use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
俞加林.用超滤法制备中药浸膏制剂.中药材第12卷 第5期.1989,第12卷(第5期),参见第45页左栏第29行至右栏第7行.
俞加林.用超滤法制备中药浸膏制剂.中药材第12卷 第5期.1989,第12卷(第5期),参见第45页左栏第29行至右栏第7行. *
张兆旺等.中药药剂学 第1版.中国中医药出版社,2003,第119、120页.
张兆旺等.中药药剂学 第1版.中国中医药出版社,2003,第119、120页. *

Also Published As

Publication number Publication date
CN1778334A (en) 2006-05-31

Similar Documents

Publication Publication Date Title
CN1778334B (en) Chinese Medicine Dropping Pills for Treating Angina Pectoris of Coronary Heart Disease
CN1778343B (en) A drug drop pill for treating coronary heart disease
CN1778340B (en) Chinese medicine composition for treating coronary heart disease and angina cordis
CN1778354B (en) Chinese medicine dropping ball for coronary heart disease and angina cordis
CN1778333B (en) Traditional Chinese Medicine for Treating Angina Pectoris of Coronary Heart Disease
CN1778341B (en) A drug drop pill for treating angina pectoris of coronary heart disease
CN1778337B (en) A kind of preparation method of compound salvia miltiorrhiza tablet
CN1778339B (en) Drug drop pills for treating angina pectoris of coronary heart disease
CN1778353B (en) A kind of traditional Chinese medicine dripping pill for treating cardiovascular disease
CN1778345B (en) Chinese Medicine Dropping Pills for Treating Coronary Heart Disease
CN1778338B (en) Chinese medicine composition for treating coronary heart disease and angina cordis
CN1778327B (en) Drug dripping pills for the treatment of cardiovascular diseases
CN1778322B (en) A drug for the treatment of cardiovascular disease
CN1778346B (en) A drug for treating coronary heart disease
CN1778352B (en) Chinese medicine composition for treating cardiovascular disease
CN1778347B (en) A kind of traditional Chinese medicine dripping pill for treating coronary heart disease
CN1778344B (en) drugs for coronary heart disease
CN1778335A (en) A kind of traditional Chinese medicine for treating angina pectoris of coronary heart disease
CN1778323B (en) A drug drop pill for treating cardiovascular disease
CN101085021B (en) Medicinal composition containing safflower and radix astragali, preparation method and preparation
CN1778342A (en) A kind of traditional Chinese medicine composition for treating coronary heart disease
CN101084992B (en) Medicinal composition containing safflower and ginseng, preparation method and preparation
CN1778326B (en) Medicine for treating cardiovascular disease
CN101084994B (en) Medicinal composition containing red sage root and ginseng, preparation method and preparation
CN101085023A (en) Medicinal composition containing red sage root and dalbergia, preparation method and preparation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD.

Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white

Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd.

Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white

Patentee before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white

Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd.

Address before: 300402 Tianjin City, Beichen science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white

Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd.

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20100512